Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression

A case report

Mustafa M. Husain, Diane Stegman, Kenneth Trevino

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Depression during pregnancy can have significant health consequences for the mother and her infant. Antidepressant medications, which pass through the placenta, may increase the risk of low birth weight and preterm delivery. The use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy may induce serotonergic symptoms in the infant after delivery. Antidepressant medications in breast milk may also be passed to an infant. Vagus nerve stimulation (VNS) therapy is an effective non-pharmacologic treatment for treatment-resistant depression (TRD), but little information exists regarding the use of VNS therapy during pregnancy. Case presentation: The patient began receiving VNS therapy for TRD in March 1999. The therapy was effective, producing substantial reductions in depressive symptoms and improvement of function. In 2002, the patient reported that she was pregnant. She continued receiving VNS therapy throughout her pregnancy, labor, and delivery, which enabled the sustained remission of her depression. The pregnancy was uneventful; a healthy daughter was delivered at full term. Conclusion: In this case, VNS therapy provided effective treatment for TRD during pregnancy and delivery. VNS was safe for the patient and her child.

Original languageEnglish (US)
Article number16
JournalAnnals of General Psychiatry
Volume4
Issue number1
DOIs
StatePublished - Sep 16 2005

Fingerprint

Vagus Nerve Stimulation
Treatment-Resistant Depressive Disorder
Depression
Pregnancy
Therapeutics
Antidepressive Agents
Serotonin Uptake Inhibitors
Low Birth Weight Infant
Human Milk
Nuclear Family
Placenta
Mothers
Health

ASJC Scopus subject areas

  • Medicine(all)
  • Psychiatry and Mental health

Cite this

Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression : A case report. / Husain, Mustafa M.; Stegman, Diane; Trevino, Kenneth.

In: Annals of General Psychiatry, Vol. 4, No. 1, 16, 16.09.2005.

Research output: Contribution to journalArticle

@article{d51f85efa7764f6e8b7bf60a43903dff,
title = "Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression: A case report",
abstract = "Background: Depression during pregnancy can have significant health consequences for the mother and her infant. Antidepressant medications, which pass through the placenta, may increase the risk of low birth weight and preterm delivery. The use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy may induce serotonergic symptoms in the infant after delivery. Antidepressant medications in breast milk may also be passed to an infant. Vagus nerve stimulation (VNS) therapy is an effective non-pharmacologic treatment for treatment-resistant depression (TRD), but little information exists regarding the use of VNS therapy during pregnancy. Case presentation: The patient began receiving VNS therapy for TRD in March 1999. The therapy was effective, producing substantial reductions in depressive symptoms and improvement of function. In 2002, the patient reported that she was pregnant. She continued receiving VNS therapy throughout her pregnancy, labor, and delivery, which enabled the sustained remission of her depression. The pregnancy was uneventful; a healthy daughter was delivered at full term. Conclusion: In this case, VNS therapy provided effective treatment for TRD during pregnancy and delivery. VNS was safe for the patient and her child.",
author = "Husain, {Mustafa M.} and Diane Stegman and Kenneth Trevino",
year = "2005",
month = "9",
day = "16",
doi = "10.1186/1744-859X-4-16",
language = "English (US)",
volume = "4",
journal = "Annals of General Psychiatry",
issn = "1744-859X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression

T2 - A case report

AU - Husain, Mustafa M.

AU - Stegman, Diane

AU - Trevino, Kenneth

PY - 2005/9/16

Y1 - 2005/9/16

N2 - Background: Depression during pregnancy can have significant health consequences for the mother and her infant. Antidepressant medications, which pass through the placenta, may increase the risk of low birth weight and preterm delivery. The use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy may induce serotonergic symptoms in the infant after delivery. Antidepressant medications in breast milk may also be passed to an infant. Vagus nerve stimulation (VNS) therapy is an effective non-pharmacologic treatment for treatment-resistant depression (TRD), but little information exists regarding the use of VNS therapy during pregnancy. Case presentation: The patient began receiving VNS therapy for TRD in March 1999. The therapy was effective, producing substantial reductions in depressive symptoms and improvement of function. In 2002, the patient reported that she was pregnant. She continued receiving VNS therapy throughout her pregnancy, labor, and delivery, which enabled the sustained remission of her depression. The pregnancy was uneventful; a healthy daughter was delivered at full term. Conclusion: In this case, VNS therapy provided effective treatment for TRD during pregnancy and delivery. VNS was safe for the patient and her child.

AB - Background: Depression during pregnancy can have significant health consequences for the mother and her infant. Antidepressant medications, which pass through the placenta, may increase the risk of low birth weight and preterm delivery. The use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy may induce serotonergic symptoms in the infant after delivery. Antidepressant medications in breast milk may also be passed to an infant. Vagus nerve stimulation (VNS) therapy is an effective non-pharmacologic treatment for treatment-resistant depression (TRD), but little information exists regarding the use of VNS therapy during pregnancy. Case presentation: The patient began receiving VNS therapy for TRD in March 1999. The therapy was effective, producing substantial reductions in depressive symptoms and improvement of function. In 2002, the patient reported that she was pregnant. She continued receiving VNS therapy throughout her pregnancy, labor, and delivery, which enabled the sustained remission of her depression. The pregnancy was uneventful; a healthy daughter was delivered at full term. Conclusion: In this case, VNS therapy provided effective treatment for TRD during pregnancy and delivery. VNS was safe for the patient and her child.

UR - http://www.scopus.com/inward/record.url?scp=27644589185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644589185&partnerID=8YFLogxK

U2 - 10.1186/1744-859X-4-16

DO - 10.1186/1744-859X-4-16

M3 - Article

VL - 4

JO - Annals of General Psychiatry

JF - Annals of General Psychiatry

SN - 1744-859X

IS - 1

M1 - 16

ER -